Literature DB >> 19041284

Quantification of isradipine in human plasma using LC-MS/MS for pharmacokinetic and bioequivalence study.

Jin-Hee Park1, Yoo-Sin Park, Si-Youn Rhim, Ok-Hwa Jhee, Shin-Hee Kim, Seok-Chul Yang, Min-Ho Lee, Leslie M Shaw, Ju-Seop Kang.   

Abstract

A highly sensitive and rapid method for the analysis of isradipine in human plasma using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was developed. The procedure involves a simple liquid-liquid extraction of isradipine and amlodipine (IS, internal standard) with methyl-t-butyl ether after alkaline treatment and separation by RP-HPLC. Detection was performed by positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 372.1-->m/z 312.2 and m/z 408.8-->m/z 237.9, for quantification of isradipine and IS, respectively. The standard calibration curves showed good linearity within the range of 10 to 5000 pg/mL (r(2)>or=0.9998). The lower limit of quantitation (LLOQ) was 10 pg/mL. The retention times of isradipine (0.81 min) and IS (0.65 min) suggested the potential for high throughput of the proposed method. In addition, no significant metabolic compounds were found to interfere with the analysis. This method offered good precision and accuracy and was successfully applied for the pharmacokinetic and bioequivalence studies of 5 mg of sustained-release isradipine in 24 healthy Korean volunteers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041284     DOI: 10.1016/j.jchromb.2008.11.021

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  9 in total

1.  The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.

Authors:  E Ilijic; J N Guzman; D J Surmeier
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

2.  Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.

Authors:  Jaime N Guzman; Ema Ilijic; Ben Yang; Javier Sanchez-Padilla; David Wokosin; Dan Galtieri; Jyothisri Kondapalli; Paul T Schumacker; D James Surmeier
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

3.  Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease.

Authors:  Nadine J Ortner; Gabriella Bock; Antonios Dougalis; Maria Kharitonova; Johanna Duda; Simon Hess; Petronel Tuluc; Thomas Pomberger; Nadia Stefanova; Florian Pitterl; Thomas Ciossek; Herbert Oberacher; Henning J Draheim; Peter Kloppenburg; Birgit Liss; Jörg Striessnig
Journal:  J Neurosci       Date:  2017-06-07       Impact factor: 6.167

4.  L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease.

Authors:  Thimmappa S Anekonda; Joseph F Quinn; Christopher Harris; Kate Frahler; Teri L Wadsworth; Randall L Woltjer
Journal:  Neurobiol Dis       Date:  2010-09-09       Impact factor: 5.996

Review 5.  Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

Authors:  Thimmappa S Anekonda; Joseph F Quinn
Journal:  Biochim Biophys Acta       Date:  2011-09-08

6.  Phytic acid as a potential treatment for alzheimer's pathology: evidence from animal and in vitro models.

Authors:  Thimmappa S Anekonda; Teri L Wadsworth; Robert Sabin; Kate Frahler; Christopher Harris; Babett Petriko; Martina Ralle; Randy Woltjer; Joseph F Quinn
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

7.  Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling.

Authors:  Kyle H Moore; John S Clemmer
Journal:  Am J Physiol Renal Physiol       Date:  2021-09-06

8.  A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease: isradipine as a candidate drug.

Authors:  Philip F Copenhaver; Thimmappa S Anekonda; Derek Musashe; Kristine M Robinson; Jenna M Ramaker; Tracy L Swanson; Teri L Wadsworth; Doris Kretzschmar; Randall L Woltjer; Joseph F Quinn
Journal:  Dis Model Mech       Date:  2011-05-19       Impact factor: 5.758

Review 9.  L-type calcium channels as drug targets in CNS disorders.

Authors:  Nadine J Ortner; Jörg Striessnig
Journal:  Channels (Austin)       Date:  2015-06-03       Impact factor: 2.581

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.